Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04461938 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Characterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3)

Study acronym: ERGO3
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Dec 31, 2023 to Jun 30, 2025 Study site revisedv5 Show 1 more changeShow less
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Recruiting to Active, Not Recruiting Primary completion date changed from estimate of Dec 2022 to Dec 31, 2022 · Completion date: Dec 2022 to Dec 31, 2023 · Site details revisedv4 Show 3 more changesShow less
    • Primary completion date changed from estimate of Dec 2022 to Dec 31, 2022
    • Completion date: Dec 2022 to Dec 31, 2023
    • Site details revised
  3. Enrollment target: 15 to 30 Primary and study completion dates: Mar 2022 to Dec 2022 · Primary endpoints revised (4)v3 Show 2 more changesShow less
    • Primary and study completion dates: Mar 2022 to Dec 2022
    • Primary endpoints revised (4)

    See this version in full on ClinicalTrials.gov ↗

  4. Start date changed from estimate of Jul 2020 to Aug 19, 2020v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Goethe University
21 trials monitored
See 1 trial at risk
Glioma
668 trials monitored
See 40 trials at risk
Nutritional interventions such as ketogenic diet (KD) or fasting are currently under evaluation as anti-cancer treatment. In glioma patient cohorts, the feasibility and safety of fasting in addition to antitumor treatment has been shown. However, it is still unclear whether fasting exerts effects on the glioma tumor tissue at all, and whether fasting causes metabolic or immunological changes in the glioma microenvironment that could be exploited therapeutically. Therefore, the central contribution of this study is to characterize metabolic and immunological changes in the glioma tumor tissue induced by a fasting cycle of 72 hours prior to biopsy or resection.
Trial Details
NCT Number NCT04461938
Lead Sponsor Goethe University
Conditions Glioma, Mixed
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov